Sheryl L. Conley
Known title: DirectorCIK: 0001238659
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
Transaction History
| ANIK | ▲ Buy | Grant | 10,402 | $0 | 6/18/2026 | View on chart |
| STIM | ▲ Buy | Grant | 30,000 | $0 | 5/28/2026 | View on chart |
| STIM | ▲ Buy | Grant | 7,326 | $0 | 10/20/2025 | View on chart |
| ANIK | ▲ Buy | Grant | 14,164 | $0 | 6/20/2025 | View on chart |
| STIM | ▲ Buy | Grant | 30,000 | — | 5/22/2025 | View on chart |
| STIM | ▼ Sell | Other | 44,444 | $100K | 2/7/2025 | View on chart |
| ANIK | ▲ Buy | Grant | 5,771 | $0 | 7/9/2024 | View on chart |
| STIM | ▲ Buy | Grant | 25,000 | — | 5/30/2024 | View on chart |
| ANIK | ▲ Buy | Grant | 6,500 | $0 | 6/14/2023 | View on chart |
| STIM | ▲ Buy | Grant | 36,364 | — | 5/25/2023 | View on chart |
| ANIK | ▲ Buy | Grant | 7,954 | $0 | 6/8/2022 | View on chart |
| STIM | ▲ Buy | Grant | 38,910 | — | 5/26/2022 | View on chart |
| ANIK | ▲ Buy | Grant | 8,179 | $0 | 10/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News
Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.